Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: Current status

Archivum Immunologiae et Therapiae Experimentalis

Volumn 60, Issue 1, 2012, Pages 31-41

  Deeg, H Joachim ^a,b   Bartenstein, Matthias ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Age; Comorbidities; Conditioning intensity; Relapse; Transplantation for MDS

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALEMTUZUMAB; AZACITIDINE; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHEMOTHERAPY; CHRONIC GRAFT VERSUS HOST DISEASE; COMORBIDITY; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; DONOR SELECTION; FLOW CYTOMETRY; GENOTYPE; GRAFT VERSUS HOST REACTION; HEALTH CARE MANAGEMENT; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; IRON OVERLOAD; IRRADIATION; MYELODYSPLASTIC SYNDROME; RADIOIMMUNOTHERAPY; REVIEW; RISK ASSESSMENT; SURVIVAL RATE;

CYTOGENETIC ANALYSIS; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYELODYSPLASTIC SYNDROMES; RECURRENCE; RISK FACTORS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84858794809     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-011-0152-z     Document Type: Review

References (114)

1. Al-Ali HK, Brand R, van Biezen A et al (2007) A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia 21:1945-1951 (Pubitemid 47299968)
2. Alessandrino EP, Della Porta MG, Bacigalupo A et al (2008) WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 112:895-902
3. Alyea EP, Kim HT, Ho V et al (2006) Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 12:1047-1055 (Pubitemid 44603937)
4. Armand P, Kim HT, Cutler CS et al (2007a) Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 109:4586-4588 (Pubitemid 46743431)
5. Armand P, Kim HT, DeAngelo DJ et al (2007b) Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant 13:655-664 (Pubitemid 46767993)
6. Armand P, Kim HT, Cutler CS et al (2008) A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 14:28-35 (Pubitemid 350286734)
7. Armand P, Deeg HJ, Kim HT et al (2010) Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes. Bone Marrow Transplant 45:877-885
8. Aversa F (2008) Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States (Review). Bone Marrow Transplant 41:473-481
9. Bacher U, Zander AR, Haferlach T et al (2008) Minimal residual disease diagnostics in myeloid malignancies in the post transplant period (Review). Bone Marrow Transplant 42:145-157
10. Barker JN, Weisdorf DJ, Defor TE et al (2005) Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105:1343-1347 (Pubitemid 40170912)
11. Baron F, Sandmaier BM (2005) Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning. Curr Opin Hematol 12:435-443 (Pubitemid 41546473)
12. Bartenstein M, Deeg HJ (2010) Hematopoietic stem cell transplantation for MDS. Hematol Oncol Clin North Am 24:407-422
13. Beelen DW, Trenschel R, Casper J et al (2005) Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 35:233-241 (Pubitemid 40268293)
14. Beran M (2000) Intensive chemotherapy for patients with high-risk myelodysplastic syndrome (Review). Int J Hematol 72:139-150
15. Breccia M, Cannella L, Stefanizzi C et al (2009) WPSS versus simplified myelodysplastic syndrome risk score: which is the best tool for prediction of survival in myelodysplastic patients? Leuk Res 33:e93-e94
16. Brunstein CG, Weisdorf DJ (2009) Future of cord blood for oncology uses (Review). Bone Marrow Transplant 44:699-707
17. Brunstein CG, Gutman JA, Weisdorf DJ et al (2010) Allogeneic hematopoietic cell transplantation for hematological malignancy: relative risks and benefits of double umbilical cord blood. Blood 116:4693-4699
18. Busca A, Falda M, Manzini P et al (2010) Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy. Biol Blood Marrow Transplant 16:115-122
19. Campregher PV, Gooley T, Scott BL et al (2007) Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation. Bone Marrow Transplant 40:965-971 (Pubitemid 350048195)
20. Casper J, Wolff D, Knauf W et al (2010) Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. J Clin Oncol 28:3344-3351
21. Castro-Malaspina H, Harris RE, Gajewski J et al (2002) Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 99:1943-1951 (Pubitemid 34525473)
22. Cazzola M, Della Porta MG, Malcovati L (2008) Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes (Review). Hematology Am Soc Hematol Educ Program 2008:166-175
23. Chang C, Storer BE, Scott BL et al (2007) Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 110:1379-1387 (Pubitemid 47281440)
24. Cutler CS, Lee SJ, Greenberg P et al (2004) A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104:579-585 (Pubitemid 38900045)
25. de Lima M, Giralt S (2006) Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome (Review). Semin Hematol 43:107-117
26. de Lima M, Anagnostopoulos A, Munsell M et al (2004a) Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104:865-872 (Pubitemid 38970586)
27. de Lima M, Couriel D, Thall PF et al (2004b) Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104:857-864 (Pubitemid 38970585)
28. de Lima M, Giralt S, Thall PF et al (2010) Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 116:5420-5431
29. De Padua SL, de Lima M, Kantarjian H et al (2009) Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 43:839-843
30. De Roos AJ, Deeg HJ, Onstad L et al (2010) Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005-2006. Am J Hematol 85:765-770
31. de Witte T, Hermans J, Vossen J et al (2000) Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 110:620-630
32. de Witte T, Brand R, van Biezen A et al (2009) Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival. Br J Haematol 146:627-636
33. Deeg HJ (2009a) Hematopoietic cell transplantation for myelodysplastic syndrome and myeloproliferative disorders. In: Appelbaum FR, Forman SJ, Negrin RS et al (eds) Thomas' hematopoietic cell transplantation. Wiley-Blackwell, Oxford, pp 827-844
34. Deeg HJ (2009b) Transplant conditioning regimens: can we say it better? (Editorial). Biol Blood Marrow Transplant 15:653-655
35. Deeg HJ, Sandmaier BM (2010) Who is fit for allogeneic transplantation? Blood 116:4762-4770
36. Deeg HJ, Storer B, Slattery JT et al (2002) Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100:1201-1207 (Pubitemid 34864272)
37. Deeg HJ, Maris MB, Scott BL et al (2006) Optimization of allogeneic transplant conditioning: not the time for dogma. Leukemia 20:1701-1705 (Pubitemid 44590959)
38. Delaney C, Gutman JA, Appelbaum FR (2009) Cord blood transplantation for haematological malignancies: conditioning regimens, double cord transplant and infectious complications (Review). Br J Haematol 147:207-216
39. Depil S, Deconinck E, Milpied N et al (2004) Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome. Bone Marrow Transplant 33:531-534 (Pubitemid 38425784)
40. Diez-Campelo M, Perez-Simon JA, Perez J et al (2009) Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies. Am J Hematol 84:149-152
41. Farina L, Bruno B, Patriarca F et al (2009) The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia 23:1131-1138
42. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al (2009) Efficacy of azacitidine comparedwith that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223-232
43. Gattermann N (2009) The treatment of secondary hemochromatosis. Dtsch Arztebl Int 106:499-504
44. Gooley TA, Chien JW, Pergam SA et al (2010) Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 363:2091-2101
45. Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088 [erratum appears in Blood 1998 91:1100] (Pubitemid 27132124)
46. Greenberg PL, Baer MR, Bennett JM et al (2006) Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw 4:58-77 [erratum appears in J Natl Compr Canc Netw 2006 Mar 4(3):table of contents Note: dosage error in text] (Pubitemid 44265381)
47. Guardiola P, Runde V, Bacigalupo A et al (2002) Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 99:4370-4378 (Pubitemid 34627203)
48. Guilfoyle R, Demers A, Bredeson C et al (2009) Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center. Bone Marrow Transplant 43:133-139
49. Hamblin TJ (2002) Epidemiology of the myelodysplastic syndromes. In: Bennett JM (ed) The myelodysplastic syndromes: pathobiology and clinical management. Marcel Dekker, Inc, New York, pp 15-27
50. Harrison SJ, Cook G, Nibbs RJ et al (2006) Immunotherapy of multiple myeloma: the start of a long and tortuous journey (Review). Expert Rev Anticancer Ther 6:1769-1785 (Pubitemid 46062312)
51. Kang Y, Chao NJ, Aversa F (2008) Unmanipulated or CD34 selected haplotype mismatched transplants (Review). Curr Opin Hematol 15:561-567
52. Kantarjian H, O'Brien S, Ravandi F et al (2008) Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 113:1351-1361
53. Kasamon YL, Luznik L, Leffell MS et al (2010) Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 16:482-489
54. Kataoka K, Nannya Y, Hangaishi A et al (2009) Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15:195-204
55. Kataoka K, Nannya Y, Ueda K et al (2010) Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study. Bone Marrow Transplant 45:513-520
56. Kawase T, Matsuo K, Kashiwase K et al (2009) HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism. Blood 113:2851-2858
57. Kelly SS, Sola CB, de Lima M et al (2009) Ex vivo expansion of cord blood (Review). Bone Marrow Transplant 44:673-681
58. Kindwall-Keller T, Isola LM (2009) The evolution of hematopoietic SCT in myelodysplastic syndrome (Review). Bone Marrow Transplant 43:597-609
59. Koh LP, Chao NJ (2004) Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens (Review). Biol Blood Marrow Transplant 10:1-22
60. Laport GG, Sandmaier BM, Storer BE et al (2008) Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant 14:246-255
61. Lee JW, Kang HJ, Kim EK et al (2009) Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children. Bone Marrow Transplant 44:793-797
62. Lee JH, Lee JH, Lim SN et al (2010) Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity. Bone Marrow Transplant 45:450-457
63. Lim ZY, Ho AY, Ingram W et al (2006) Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br J Haematol 135:201-209 (Pubitemid 44401617)
64. Lim ZY, Pearce L, Ho AY et al (2007) Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoietic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. Br J Haematol 138:517-526 (Pubitemid 47063029)
65. Litzow MR, Tarima S, Perez WS et al (2010) Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 115:1850-1857
66. Luznik L, O'Donnell PV, Symons HJ et al (2008) HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 14:641-650 (Pubitemid 351664058)
67. Mahindra A, Bolwell B, Sobecks R et al (2009) Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Br J Haematol 146:310-316
68. Malcovati L, Germing U, Kuendgen A et al (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503-3510 (Pubitemid 47315575)
69. Maradei SC, Maiolino A, de Azevedo AM et al (2009) Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood 114:1270-1275
70. Marcondes M, Deeg HJ (2008) Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): when, how and for whom? Best Pract Res Clin Haematol 21:67-77 (Pubitemid 351377509)
71. Maris MB, Sandmaier BM, Storer BE et al (2004) Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104:3535-3542 (Pubitemid 39564424)
72. Martino R, Iacobelli S, Brand R et al (2006) Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108:836-846 (Pubitemid 44154615)
73. Michalek J, Collins RH, Durrani HP et al (2003) Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences. Proc Natl Acad Sci USA 100:1180-1184 (Pubitemid 36183976)
74. Mills KI, Kohlmann A, Williams PM et al (2009) Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood 114:1063-1072
75. Nachtkamp K, Kundgen A, Strupp C et al (2009) Impact on survival of different treatments for myelodysplastic syndromes (MDS). Leuk Res 33:1024-1028
76. Nakai K, Kanda Y, Fukuhara S et al (2005) Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia 19:396-401 (Pubitemid 40403316)
77. Nemecek ER, Guthrie KA, Sorror ML et al (2011) Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant 17:341-350
78. O'Donnell P, Luznik L, Symons H (2006) Favorable outcome of patients with relapsed Hodgkin lymphoma (HL) after nonmyeloablative hematopoietic cell transplantation (NM-HCT) using related haploidentical donors. Blood 108(Part 1):894a-895a #3135 (Abstract)
79. O'Donnell PV, Harrington E, Gooley TA et al (2010) Cyclophosphamide- induced tolerance following bone marrow transplantation from haploidentical donors. Haematologica Edición Española 95(Extra 1):266-271
80. Oliansky DM, Antin JH, Bennett JM et al (2009) The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant 15:137-172
81. Ooi J (2006) The efficacy of unrelated cord blood transplantation for adult myelodysplastic syndrome. Leuk Lymphoma 47:599-602
82. Ooi J, Iseki T, Takahashi S et al (2003) Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. Blood 101:4711-4713 (Pubitemid 36857725)
83. Parimon T, Au DH, Martin PJ et al (2006) A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 144:407-414 (Pubitemid 46768162)
84. Petersdorf EW (2009) Hematopoietic cell transplantation from unrelated donors. In: Appelbaum FR, Forman SJ, Negrin RS et al (eds) Blume thomas' hematopoietic cell transplantation. Wiley-Blackwell, Oxford, pp 675-691
85. Pidala J, Anasetti C, Kharfan-Dabaja MA et al (2009a) Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 15:1415-1421
86. Pidala J, Kim J, Field T et al (2009b) Infliximab for managing steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 15:1116-1121
87. Ramakrishnan A, Deeg HJ (2008) Allogeneic hematopoietic cell transplantation for patients with myelodysplastic syndrome and myeloproliferative disorders. In: Soiffer RJ (ed) Hematopoietic stem cell transplantation. Humana Press, Totowa, pp 167-182
88. Rizzieri DA, Koh LP, Long GD et al (2007) Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 25:690-697 (Pubitemid 350002925)
89. Rocha V, Gluckman E (2009) Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol 147:262-274
90. Rocha V, Locatelli F (2008) Searching for alternative hematopoietic stem cell donors for pediatric patients (Review). Bone Marrow Transplant 41:207-214 (Pubitemid 351188919)
91. Samuelson S, Sandmaier BM, Heslop HE et al (2011) Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. Br J Haematol 153:76-82
92. Sato A, Ooi J, Takahashi S et al (2011) Unrelated cord blood transplantation after myeloablative conditioning in adults with advanced myelodysplastic syndromes. Bone Marrow Transplant 46:257-261
93. Scott B, Deeg HJ (2006) Hemopoietic cell transplantation as curative therapy of myelodysplastic syndromes and myeloproliferative disorders. Best Pract Res Clin Haematol 19:519-522
94. Scott BL, Storer B, Loken M et al (2005) Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 11:65-73 (Pubitemid 40057995)
95. Scott BL, Sandmaier BM, Storer B et al (2006) Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 20:128-135
96. Scott BL, Storer BE, Greene JE et al (2007) Marrow fibrosis as a risk factor for post-transplant outcome in patients with advanced MDS or AML with multilineage dysplasia. Biol Blood Marrow Transplant 13:345-354
97. Scott BL, Wells DA, Loken MR et al (2008) Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood 112:2681-2686
98. Shaw BE, Mufti GJ, Mackinnon S et al (2008) Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant 42:783-789
99. Sierra J, Pérez WS, Rozman C et al (2002) Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100:1997-2004 (Pubitemid 35001229)
100. Sorror M, Maris M, Baron F (2004) A modified hematopoietic cell transplantation (HCT)-specific co-morbidity index. Blood 104(Part 1):324a-325a #1146 (Abstract)
101. Sorror ML, Maris MB, Storb R et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106:2912-2919 (Pubitemid 41510773)
102. Sorror M, Storer B, Sandmaier BM et al (2008) Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 112:1992-2001 (Pubitemid 351574075)
103. Spitzer TR (2005) Haploidentical stem cell transplantation: the always present but overlooked donor. Hematol Am Soc Hematol Educ Program 2005:390-395
104. Steensma DP, Bennett JM (2006) The myelodysplastic syndromes: diagnosis and treatment (Review). Mayo Clin Proc 81:104-130 (Pubitemid 43054324)
105. Stetler-Stevenson M, Arthur DC, Jabbour N et al (2001) Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 98:979-987
106. Strasser SI, Kowdley KV, Sale GE et al (1998) Iron overload in bone marrow transplant recipients. Bone Marrow Transplant 22:167-173 (Pubitemid 28375656)
107. Sucak GT, Yegin ZA, Ozkurt ZN et al (2008) The role of liver biopsy in the workup of liver dysfunction late after SCT: is the role of iron overload underestimated? Bone Marrow Transplant 42:461-467
108. Valcarcel D, Martino R (2007) Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia (Review). Curr Opin Oncol 19:660-666 (Pubitemid 47515208)
109. Vaughn J, Storer B, Mielcarek M et al (2010) Treatment of recurrent or persistent AML/MDS after allogeneic hematopoietic cell transplantation with azacitidine. Blood 116:551 #1288 (Abstract)
110. Warlick ED, O'Donnell PV, Borowitz M et al (2008) Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res 32:1439-1447
111. Warlick ED, Cioc A, DeFor T et al (2009) Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol Blood Marrow Transplant 15:30-38
112. Wells DA, Benesch M, Loken MR et al (2003) Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hemopoietic stem cell transplantation. Blood 102:394-403 (Pubitemid 36759682)
113. Welniak LA, Blazar BR, Murphy WJ (2007) Immunobiology of allogeneic hematopoietic stem cell transplantation (Review). Annu Rev Immunol 25:139-170 (Pubitemid 46697905)
114. Yakoub-Agha I, de La Salmonière P, Ribaud P et al (2000) Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French Society of bone marrow transplantation. J Clin Oncol 18:963-971 (Pubitemid 30123771)